BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Arixtra® (fondaparinux sodium): shortage following interrupted production due to a minor defect affecting the needle guard

2017.07.18

Active substance: fondaparinux sodium

The company Aspen Pharma Trading Limited is circulating information on the fact that a minor defect affecting the needle guard of some Arixtra syringes has led to quarantine of several batches and interrupted production.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 248KB, File is accessible